Silence Therapeutics Plc (SLN) has released an update.
Silence Therapeutics Plc has reported a narrowed loss after taxation to £1,876 thousand for the first quarter of 2024 compared to £10,204 thousand in the same period last year, reflecting improved revenue and reduced operating expenses. The company’s financial position shows a significant increase in net assets, with cash and cash equivalents rising to £113,056 thousand from £54,031 thousand at the end of December 2023.
For further insights into SLN stock, check out TipRanks’ Stock Analysis page.
